​

Immunome (IMNM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IMNM Stock Forecast

Immunome (IMNM) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $28.25, with a high of $36.00 and a low of $18.00. This represents a 44.95% increase from the last price of $19.49.

$10 $16 $22 $28 $34 $40 High: $36 Avg: $28.25 Low: $18 Last Closed Price: $19.49

IMNM Stock Rating

Immunome stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

IMNM Price Target Upside V Benchmarks

TypeNameUpside
StockImmunome44.95%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts224
Avg Price Target$34.50$34.50$28.25
Last Closing Price$19.49$19.49$19.49
Upside/Downside77.01%77.01%44.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25210---12
Nov, 25210---12
Oct, 25210---12
Sep, 2528---10
Aug, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 01, 2025Karina RabayevaTruist Financial$36.00$18.4295.44%84.71%
Nov 17, 2025Stephens$33.00$17.1492.53%69.32%
Sep 05, 2025Craig-Hallum$26.00$10.52147.15%33.40%
Aug 22, 2025Evercore ISI$18.00$10.3074.76%-7.64%
Aug 13, 2024Biren AminPiper Sandler$23.00$12.6481.96%18.01%
Apr 15, 2024Michael SchmidtGuggenheim$35.00$20.5870.07%79.58%
Apr 01, 2024David NierengartenWedbush$33.00$24.6833.71%69.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 22, 2025Goldman SachsBuyinitialise
Sep 05, 2025Craig-HallumBuyinitialise
Aug 22, 2025Evercore ISIOutperforminitialise
Nov 14, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Piper SandlerOverweightinitialise
Apr 15, 2024GuggenheimBuyinitialise
Apr 01, 2024WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.69$-5.38$-5.00----
Avg Forecast$-8.63$-0.92$-4.42$-3.11$-3.21$-2.81$-1.32
High Forecast$-3.99$-0.47$-4.32$-2.48$-2.36$-1.72$-1.01
Low Forecast$-15.99$-1.19$-4.56$-4.10$-4.36$-3.97$-1.63
Surprise %-80.42%484.78%13.12%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$14.02M$9.04M----
Avg Forecast$2.10M$12.27M$9.41M$3.15M$17.90M$76.14M$223.12M
High Forecast$3.48M$14.02M$11.40M$3.71M$17.90M$76.14M$262.84M
Low Forecast$1.23M$10.50M$7.56M$2.58M$17.90M$76.14M$183.11M
Surprise %-14.28%-3.89%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-17.12M$-106.81M$-292.96M----
Avg Forecast$-171.25M$-16.47M$-88.13M$-65.26M$-66.63M$-56.45M$-26.19M
High Forecast$-79.25M$-9.41M$-85.78M$-49.16M$-46.75M$-34.13M$-20.09M
Low Forecast$-317.26M$-23.53M$-90.47M$-81.35M$-86.51M$-78.77M$-32.26M
Surprise %-90.00%548.56%232.44%----

IMNM Forecast FAQ

Is Immunome stock a buy?

Immunome stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immunome is a favorable investment for most analysts.

What is Immunome's price target?

Immunome's price target, set by 7 Wall Street analysts, averages $28.25 over the next 12 months. The price target range spans from $18 at the low end to $36 at the high end, suggesting a potential 44.95% change from the previous closing price of $19.49.

How does Immunome stock forecast compare to its benchmarks?

Immunome's stock forecast shows a 44.95% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Immunome over the past three months?

  • December 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Immunome’s EPS forecast?

Immunome's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.11, marking a -37.80% decrease from the reported $-5 in 2024. Estimates for the following years are $-3.21 in 2026, $-2.81 in 2027, and $-1.32 in 2028.

What is Immunome’s revenue forecast?

Immunome's average annual revenue forecast for its fiscal year ending in December 2025 is $3.15M, reflecting a -65.18% decrease from the reported $9.04M in 2024. The forecast for 2026 is $17.9M, followed by $76.14M for 2027, and $223.12M for 2028.

What is Immunome’s net income forecast?

Immunome's net income forecast for the fiscal year ending in December 2025 stands at $-65.257M, representing a -77.73% decrease from the reported $-293M in 2024. Projections indicate $-66.63M in 2026, $-56.449M in 2027, and $-26.194M in 2028.